argenx

Industriepark 7
9052 Zwijnaarde
BE
argenx
Foundation date
04/09/2009
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2809 '22
Neurotechnologies
Event by: VIB -
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB
Latest news
More news-
ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder
19 hours ago
Read more
-
Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody® drug discovery and development technology in rare diseases
Tuesday June 28th 2022
Read more
-
MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis
Tuesday June 28th 2022
Read more